KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Non Operating Income: 2009-2025

Historic Non Operating Income for Novavax (NVAX) over the last 11 years, with Sep 2025 value amounting to $9.2 million.

  • Novavax's Non Operating Income fell 42.36% to $9.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.3 million, marking a year-over-year increase of 15.62%. This contributed to the annual value of $40.4 million for FY2024, which is 6.72% up from last year.
  • According to the latest figures from Q3 2025, Novavax's Non Operating Income is $9.2 million, which was down 22.89% from $11.9 million recorded in Q2 2025.
  • In the past 5 years, Novavax's Non Operating Income registered a high of $64.0 million during Q4 2022, and its lowest value of -$34.8 million during Q3 2022.
  • In the last 3 years, Novavax's Non Operating Income had a median value of $10.1 million in 2025 and averaged $10.0 million.
  • The largest annual percentage gain for Novavax's Non Operating Income in the last 5 years was 14,639.86% (2022), contrasted with its biggest fall of 756.31% (2022).
  • Quarterly analysis of 5 years shows Novavax's Non Operating Income stood at $434,000 in 2021, then surged by 14,639.86% to $64.0 million in 2022, then plummeted by 82.83% to $11.0 million in 2023, then increased by 19.58% to $13.1 million in 2024, then plummeted by 42.36% to $9.2 million in 2025.
  • Its Non Operating Income stands at $9.2 million for Q3 2025, versus $11.9 million for Q2 2025 and $10.1 million for Q1 2025.